606 / 1498
•
Open-label, phase 2 study
•
125 patients with indolent non-Hodgkin’s lymphomas
•
No response to rituximab and an alkylating agent or had had a relapse
within 6 months after receipt of those therapies
|
|
606 / 1498
•
Open-label, phase 2 study
•
125 patients with indolent non-Hodgkin’s lymphomas
•
No response to rituximab and an alkylating agent or had had a relapse
within 6 months after receipt of those therapies